Novartis India Ltd

As of 06-Nov, Novartis India Ltd's stock price is Rs 840.55, down 2.04%, and has underperformed its sector and the Sensex over the past year. The stock is in a bearish trend, trading below all major moving averages, with a year-to-date decline of 8.62%.

As of November 4, 2025, Novartis India is fairly valued with a PE ratio of 19.90, lower than some peers but has underperformed the Sensex with a return of -19.75% over the past year.

As of October 31, 2025, Novartis India is considered overvalued with a PE ratio of 20.06 and negative EV ratios, indicating weaker performance compared to peers like Sun Pharma and Cipla, and a year-to-date stock return of -5.85% versus the Sensex's 7.42%.

As of October 31, 2025, Novartis India is considered overvalued with a PE ratio of 20.06 and a year-to-date return of -5.85%, underperforming compared to its peers and the Sensex.

As of October 31, 2025, Novartis India is considered overvalued with a PE ratio of 20.06, underperforming the Sensex with a year-to-date return of -5.85%, while its peers have higher or more attractive valuations.

As of October 30, 2025, Novartis India is fairly valued with a PE ratio of 19.98, a Price to Book Value of 0.27, and a PEG ratio of 0.91, despite a negative return of -18.71% over the past year compared to the Sensex's 5.58%, indicating potential challenges ahead but not overvaluation relative to its peers.

Novartis India's Q2 FY26 results show an 18.67% year-on-year net profit increase to ₹24.22 crore, but a 12.31% decline quarter-on-quarter, indicating mixed performance with revenue growth overshadowed by margin compression and operational challenges. Investors should monitor future quarters for potential improvements.

Novartis India has experienced fluctuating financial performance, with net sales declining from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, while operating profit significantly improved from INR 12.28 crore to INR 133.38 crore during the same period, indicating a recovery in profitability despite declining sales. Total assets and liabilities also decreased, reflecting reduced financial obligations.

As of October 24, 2025, Novartis India is in a bearish trend with strong indications of weakness across multiple technical indicators, including the MACD, Bollinger Bands, and moving averages, showing no immediate signs of reversal.

As of October 24, 2025, Novartis India has shifted to a bearish trend with moderate strength, indicated by bearish MACD, Bollinger Bands, and moving averages, alongside a significant underperformance of -18.20% over the past year compared to the Sensex's 5.18% return.

As of October 24, 2025, Novartis India shows a bearish trend, confirmed by multiple indicators including the MACD, Bollinger Bands, and moving averages, indicating a weak outlook in the near term.

As of 24-Sep, Novartis India Ltd's stock price is 892.00, reflecting a decline of 0.36% and a total drop of 1.58% over the last three days. The stock has underperformed the Sensex and shows high valuation concerns, leading to cautious investor sentiment.

As of 23-Sep, Novartis India Ltd's stock price is declining at 894.00, down -0.27%, and has underperformed significantly with a -16.53% return over the past year. The stock's bearish trend is influenced by high valuation concerns and low domestic mutual fund ownership, leading to investor hesitation.

As of 22-Sep, Novartis India Ltd's stock price is at 896.40, down 1.1%, indicating a bearish trend as it trades below all major moving averages. Despite strong profit growth, high valuations and low mutual fund participation suggest investor concerns and significant challenges ahead.